AU741901B2 - Insulin C-peptides - Google Patents

Insulin C-peptides Download PDF

Info

Publication number
AU741901B2
AU741901B2 AU43915/97A AU4391597A AU741901B2 AU 741901 B2 AU741901 B2 AU 741901B2 AU 43915/97 A AU43915/97 A AU 43915/97A AU 4391597 A AU4391597 A AU 4391597A AU 741901 B2 AU741901 B2 AU 741901B2
Authority
AU
Australia
Prior art keywords
peptide
seq
insulin
peptides
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU43915/97A
Other languages
English (en)
Other versions
AU4391597A (en
Inventor
Bo-Lennart Johanson
Hans Jornvall
John Wahren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creative Peptides Sweden AB
Original Assignee
Creative Peptides Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Peptides Sweden AB filed Critical Creative Peptides Sweden AB
Publication of AU4391597A publication Critical patent/AU4391597A/en
Application granted granted Critical
Publication of AU741901B2 publication Critical patent/AU741901B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU43915/97A 1996-09-27 1997-09-26 Insulin C-peptides Ceased AU741901B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus
SE9603533 1996-09-27
PCT/GB1997/002627 WO1998013384A1 (en) 1996-09-27 1997-09-26 Insulin c-peptides

Publications (2)

Publication Number Publication Date
AU4391597A AU4391597A (en) 1998-04-17
AU741901B2 true AU741901B2 (en) 2001-12-13

Family

ID=20404052

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43915/97A Ceased AU741901B2 (en) 1996-09-27 1997-09-26 Insulin C-peptides

Country Status (24)

Country Link
US (1) US6610649B2 (enExample)
EP (1) EP0938503B1 (enExample)
JP (1) JP2001500893A (enExample)
KR (1) KR20000048643A (enExample)
AT (1) ATE347562T1 (enExample)
AU (1) AU741901B2 (enExample)
BG (1) BG103362A (enExample)
BR (1) BR9711573A (enExample)
CA (1) CA2266416C (enExample)
CZ (1) CZ108599A3 (enExample)
DE (1) DE69737065T2 (enExample)
DK (1) DK0938503T3 (enExample)
ES (1) ES2278394T3 (enExample)
HU (1) HUP0000432A3 (enExample)
IL (1) IL129143A0 (enExample)
IS (1) IS5008A (enExample)
NO (1) NO991483L (enExample)
NZ (1) NZ335231A (enExample)
PL (1) PL332494A1 (enExample)
RU (1) RU2206336C2 (enExample)
SE (1) SE520392C2 (enExample)
SK (1) SK39499A3 (enExample)
TR (1) TR199900694T2 (enExample)
WO (1) WO1998013384A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022342D0 (en) * 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7384914B2 (en) * 2003-01-06 2008-06-10 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
EP1753446A4 (en) * 2004-05-27 2009-10-28 Essential Skincare Llc ALPHA-1 GLYCOPROTEIN ACID FOR THE TREATMENT OF DIABETES
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
GB0601950D0 (en) * 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
WO2008019368A2 (en) * 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
WO2009046851A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Cgrp as a therapeutic agent
GB0723250D0 (en) * 2007-11-28 2008-01-09 Univ Leeds Compositions and methods for reducing macrovascular complications in diabetic patients
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033204A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides
US8410049B2 (en) * 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
JP2013533217A (ja) 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
CA2827029C (en) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Tripeptide compositions and methods
US8962553B2 (en) 2011-11-17 2015-02-24 Cebix Ab Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
RU2522897C1 (ru) * 2013-04-16 2014-07-20 Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) * 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
CN104888201B (zh) * 2015-06-29 2018-04-27 齐锦生 用于防治糖尿病及其慢性并发症的肽类药物
ES2927977T3 (es) 2017-02-06 2022-11-14 Biotempt Bv Moduladores peptídicos de la interacción entre el péptido C humano y el receptor de elastina humana para uso terapéutico

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953415A (en) * 1972-05-15 1976-04-27 Richter Gedeon Vegyeszeti Gyar Rt Process for the preparation of biologically active polypeptides containing aspartyl group
WO1996005309A2 (en) * 1994-08-17 1996-02-22 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5210872B2 (enExample) 1973-07-14 1977-03-26
JPS55105653A (en) * 1978-10-02 1980-08-13 Shionogi & Co Ltd Tyrosyl c-peptides
US4652548A (en) * 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
IL66611A0 (en) 1981-08-27 1982-12-31 Lilly Co Eli Pharmaceutical formulations comprising human insulin and human c-peptide
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en) 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
US5364757A (en) 1990-05-21 1994-11-15 Administrators Of The Tulane Educational Fund Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
DE69327239T2 (de) 1992-04-13 2000-05-11 Oklahoma Med Res Found Methoden and reagentien zur diagnose von autoantikörpern
WO1994025071A1 (en) 1993-05-05 1994-11-10 Keith Rose Polyoxime compounds and their preparation
AT400723B (de) 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
MX9700198A (es) 1994-07-08 1997-04-30 Dartmouth College Compuestos peptidos de proinsulina para detectar y tratar diabetes tipo 1.
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
CO4600637A1 (es) 1996-03-15 1998-05-08 Corixa Corp Compuestos para inmunoterapia e inmunodiagnosis del cancer de prostata
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953415A (en) * 1972-05-15 1976-04-27 Richter Gedeon Vegyeszeti Gyar Rt Process for the preparation of biologically active polypeptides containing aspartyl group
WO1996005309A2 (en) * 1994-08-17 1996-02-22 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GEIGER ET AL, CHEM. BER., V106, P 188-192, 1973 *

Also Published As

Publication number Publication date
IS5008A (is) 1999-03-23
AU4391597A (en) 1998-04-17
CZ108599A3 (cs) 1999-08-11
HUP0000432A2 (hu) 2000-08-28
EP0938503A1 (en) 1999-09-01
RU2206336C2 (ru) 2003-06-20
TR199900694T2 (xx) 1999-06-21
SK39499A3 (en) 1999-10-08
SE520392C2 (sv) 2003-07-01
WO1998013384A1 (en) 1998-04-02
JP2001500893A (ja) 2001-01-23
SE9603533L (sv) 1998-03-28
BR9711573A (pt) 2000-01-18
DE69737065T2 (de) 2007-06-28
CA2266416A1 (en) 1998-04-02
KR20000048643A (ko) 2000-07-25
CA2266416C (en) 2008-04-29
DE69737065D1 (en) 2007-01-18
US20020107175A1 (en) 2002-08-08
US6610649B2 (en) 2003-08-26
HUP0000432A3 (en) 2000-10-30
SE9603533D0 (sv) 1996-09-27
EP0938503B1 (en) 2006-12-06
IL129143A0 (en) 2000-02-17
ATE347562T1 (de) 2006-12-15
ES2278394T3 (es) 2007-08-01
PL332494A1 (en) 1999-09-13
NO991483D0 (no) 1999-03-26
NO991483L (no) 1999-05-18
NZ335231A (en) 2000-11-24
BG103362A (en) 2000-05-31
DK0938503T3 (da) 2007-04-10

Similar Documents

Publication Publication Date Title
CA2266416C (en) Insulin c-peptides
EP2340261B1 (en) Amylin derivatives
JP4044140B2 (ja) インスリン誘導体類とその使用
RU2529952C2 (ru) Новые производные инсулина с сильно замедленным профилем время/действие
FI79786C (fi) Foerfarande foer framstaellning ett farmaceutiskt medel foer behandling av diabetes.
AU634954B2 (en) Treatment of diabetes mellitus
AU612964B2 (en) Insulin derivatives having a charge which is positive compared with the charge of human insulin at neutral pH
US20110009314A1 (en) Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
US20090023646A1 (en) GHRH analogues
US5939387A (en) Method of treating insulin resistance
HRP20040551A2 (en) Insulin molecule having protracted time action
ZA200306332B (en) Methods of treating diabetes mellitus
CA2224859A1 (en) Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US20110152183A1 (en) Derivatised hybrid peptides of amylin and salmon calcitonin
Fahrenkrug et al. Characterization and regional distribution of peptides derived from the vasoactive intestinal peptide precursor in the normal human brain
MXPA99002734A (en) Insulin c-peptides
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用
WO2023093758A1 (zh) 一种长效胰岛素类似物
MXPA97010291A (en) Binding inhibitors of insulin type growth confactor fixation proteins and methods of use for myself
MXPA97009880A (en) Apet regulatory compositions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)